3 Australian AI Healthcare Stocks Building Real Clinical Imaging Tools

US 10 year Treasury yields are sitting near multi month highs as investors reassess inflation risks and government borrowing needs. Higher long term rates can pressure broad equity valuations but also push more capital toward companies that aim to cut costs and improve productivity. AI healthcare stocks fit that story. This article walks through three Transformative AI Healthcare Stocks from our screener to help you spot potential long term winners.

The stocks covered in the list below are only a starting sample, and the full screen surfaced 4 more AI healthcare companies with equally compelling narratives that are not included here. If you want to move straight to the source and identify your own highest conviction ideas, head into the Transformative Artificial intelligence (AI) Healthcare Stocks screener.

ImExHS (ASX:IME)

ImExHS is a small A$16.9 million company that builds cloud-based imaging platforms for radiology, cardiology and pathology, while also running radiology and teleradiology services that generate the labelled scans used to train AI tools for diagnostics and workflow automation. Most revenue currently comes from Radiology at about A$19.2 million, with Software contributing around A$10 million and both segments largely tied to Latin American healthcare providers. The mix of software and data rich services gives ImExHS direct exposure to AI driven healthcare without relying solely on one revenue stream.

ImExHS may appeal to investors seeking exposure to AI in real clinical workflows rather than just a concept on a slide deck. Its AQUILA, ALULA and ANTEROS platforms and radiology services feed directly into AI enabled diagnostics. However, the stock is small, unprofitable and funded entirely through higher risk external borrowing. Analysts are currently forecasting increases in revenue and earnings over the next few years. If these forecasts are met, this could change margins and returns as more hospitals adopt AI powered imaging. The trade off is execution and governance risk, including a very new management team and recent CFO and company secretary changes in mid 2026. Investors who are comfortable balancing AI related opportunities with funding and operational risks may consider ImExHS for further research.

ImExHS sits at the intersection of real-world hospital workflows and AI, yet its A$16.9 million size means many investors may be overlooking key financial inflection points. Before forming a view on the stock, it is worth reading the 2 key rewards and 1 important warning sign

Build your own AI healthcare shortlist

ImExHS and the two other AI healthcare stocks in this article all came from the same Simply Wall St screener, but your best ideas are likely to come from filters that match your own process. Use our customisable Screener to mix valuation, growth and risk checks into your own watchlist, or jump straight into our curated Investing Ideas for ready made starting points.

Singular Health Group (ASX:SHG)

Singular Health Group builds medical imaging software that turns 2D scans into interactive 3D models and layers cloud based AI on top to help clinicians move toward automated diagnostics and treatment planning. Its revenue of about A$1 million currently comes from the provision and development of this medical technology, while the company has a market value of roughly A$57 million.

Singular Health Group gives you direct exposure to AI applied to real medical images, not just background infrastructure, through its AI in the Cloud platform that hosts and runs diagnostic models on 2D and 3D scans. The appeal is clear for investors who see value in faster, more accurate diagnostics and richer pre surgical planning. The challenge is that revenue is still under A$1 million, losses are ongoing and the cash runway is under a year, so further funding is likely to be a key part of the story. If the company can convert clinical interest in AI assisted imaging into scalable contracts while managing its balance sheet, the gap between today’s size and its AI ambitions could be where the opportunity lies.

Singular Health Group’s push to turn low current revenue into scalable AI imaging contracts is only half the story. Before you decide how it fits your watchlist, read the 4 warning signs (3 are major!)

Artrya (ASX:AYA)

Artrya is a medical technology company focused on using artificial intelligence to detect and diagnose coronary artery disease from coronary CT angiography scans. Its Salix platform is a cloud based AI software suite that automates coronary artery disease detection, directly aligning the business with AI enabled diagnostics in cardiology. The company currently reports about A$0.03 million in revenue from development of its AI driven CCTA image analysis technology in Australia and has a market value of roughly A$758 million.

Artrya may suit investors seeking direct exposure to AI applications in cardiology, specifically in how cardiologists detect and manage heart attack risk. The Salix platform targets subscription and fee per scan revenue from coronary CT angiography, supported by clinical use of these scans and the SAPPHIRE real world study that could build evidence for wider adoption. At the same time, revenue is still small, losses are sizeable and competitors such as HeartFlow and Cleerly are already active, so execution risk remains a key consideration. The combination of a sizeable cash balance, no debt and a clear focus on a single cardiac use case creates a tension that the recent earnings update only partly addresses.

Artrya’s sizeable cash balance and single focus on AI driven coronary diagnostics could be masking a very different risk reward profile than its tiny current revenue suggests. Before this story moves again, read the 3 key rewards and 3 important warning signs (2 are major!)

Seeking Fresh Alternatives Beyond AI?

Markets move fast and the best breakout ideas do not stay under the radar for long. Scan these fresh stock lists before momentum is fully caught and consider reviewing them promptly.

• Spot income opportunities that might be flying under most radars by reviewing our curated 6 dividend fortresses before yields change and the crowd turns up.
• Track early movers in artificial intelligence infrastructure by scanning the hand picked 56 AI infrastructure stocks while these enablers of AI demand remain under the radar for now.
• Pursue growth stories tied to real-world automation trends by checking the carefully filtered 37 robotics and automation stocks before their next contracts attract additional attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com